Mabel Ryder

5.8k total citations
57 papers, 2.6k citations indexed

About

Mabel Ryder is a scholar working on Endocrinology, Diabetes and Metabolism, Oncology and Surgery. According to data from OpenAlex, Mabel Ryder has authored 57 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Endocrinology, Diabetes and Metabolism, 23 papers in Oncology and 15 papers in Surgery. Recurrent topics in Mabel Ryder's work include Thyroid Cancer Diagnosis and Treatment (34 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Neuroendocrine Tumor Research Advances (6 papers). Mabel Ryder is often cited by papers focused on Thyroid Cancer Diagnosis and Treatment (34 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Neuroendocrine Tumor Research Advances (6 papers). Mabel Ryder collaborates with scholars based in United States, Canada and Denmark. Mabel Ryder's co-authors include James A. Fagin, Camilo Jiménez, Jeffrey A. Knauf, Maria E. Cabanillas, Ronald Ghossein, Lisa A. Kottschade, Keith C. Bible, Margaret K. Callahan, Michael A. Postow and Jedd D. Wolchok and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Mabel Ryder

53 papers receiving 2.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mabel Ryder United States	23	1.5k	1.3k	564	448	356	57	2.6k
Valeriano Leite Portugal	28	1.7k 1.2×	750 0.6×	667 1.2×	321 0.7×	226 0.6×	121	2.5k
Julio C. Ricarte‐Filho United States	14	2.4k 1.6×	952 0.7×	832 1.5×	205 0.5×	356 1.0×	29	3.1k
Raffaele Ciampi Italy	30	2.3k 1.6×	1.1k 0.8×	1.1k 2.0×	346 0.8×	355 1.0×	69	3.1k
Valeria Bottici Italy	27	2.7k 1.9×	746 0.6×	644 1.1×	651 1.5×	259 0.7×	58	3.2k
Manoj Gandhi United States	21	2.5k 1.7×	1.2k 0.9×	1.2k 2.2×	199 0.4×	259 0.7×	32	3.4k
Michael Rivera United States	24	1.8k 1.2×	624 0.5×	472 0.8×	185 0.4×	273 0.8×	61	2.5k
Ginesa García‐Rostán Spain	20	1.2k 0.8×	636 0.5×	765 1.4×	116 0.3×	147 0.4×	27	1.9k
Fatima Rangwala United States	14	421 0.3×	557 0.4×	618 1.1×	265 0.6×	284 0.8×	34	1.6k
Ida Rapa Italy	27	518 0.4×	1.1k 0.8×	828 1.5×	580 1.3×	719 2.0×	66	2.5k
Matthew A. Nehs United States	23	848 0.6×	432 0.3×	400 0.7×	100 0.2×	133 0.4×	54	1.5k

Countries citing papers authored by Mabel Ryder

Since Specialization

Citations

This map shows the geographic impact of Mabel Ryder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mabel Ryder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mabel Ryder more than expected).

Fields of papers citing papers by Mabel Ryder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mabel Ryder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mabel Ryder. The network helps show where Mabel Ryder may publish in the future.

Co-authorship network of co-authors of Mabel Ryder

This figure shows the co-authorship network connecting the top 25 collaborators of Mabel Ryder. A scholar is included among the top collaborators of Mabel Ryder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mabel Ryder. Mabel Ryder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Leboulleux, Sophie, Laura Boucai, Naifa L. Busaidy, et al.. (2025). Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement. The Lancet Diabetes & Endocrinology. 13(6). 516–527. 1 indexed citations

Morris, John C., Aditi Kumar, Ashish V. Chintakuntlawar, et al.. (2024). Pemetrexed‐carboplatin salvage therapy in advanced thyroid cancers. Head & Neck. 47(3). 813–821. 1 indexed citations

Foster, Trenton R., Robert A. Vierkant, Melanie L. Lyden, et al.. (2024). Hürthle cell (Oncocytic) carcinoma – Is hemithyroidectomy enough?. 1(1). 100010–100010.

Bogsrud, Trond Velde, et al.. (2024). Risk of malignancy in thyroid nodules with increased 11C-Choline uptake detected incidentally on PET/CT: A diagnostic accuracy study. Medicine. 103(36). e39602–e39602. 2 indexed citations

Konda, Bhavana, Eric J. Sherman, Erminia Massarelli, et al.. (2024). Cabozantinib Plus Ipilimumab/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid Cancer. The Journal of Clinical Endocrinology & Metabolism. 110(3). 830–837. 4 indexed citations

Kotwal, Anupam, Michael P. Gustafson, Svetlana Bornschlegl, et al.. (2024). Circulating immunophenotypes are potentially prognostic in follicular cell-derived thyroid cancer. Frontiers in Immunology. 14. 1325343–1325343. 6 indexed citations

Abrahão, Renata, Ann Brunson, Kathryn J. Ruddy, et al.. (2024). Late endocrine diseases in survivors of adolescent and young adult cancer in California: a population-based study. British Journal of Cancer. 130(7). 1166–1175. 5 indexed citations

Boucai, Laura, Mahesh Saqcena, Fengshen Kuo, et al.. (2023). Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy. Clinical Cancer Research. 29(8). 1620–1630. 23 indexed citations

Tella, Sri Harsha, John C. Morris, Michael Rivera, Sounak Gupta, & Mabel Ryder. (2023). THU535 Anti-angiogenic Multi-kinase Inhibitor In NUTM1 Rearranged Carcinoma Of Thyroid. Journal of the Endocrine Society. 7(Supplement_1).

10.

Parvinian, Ahmad, Jeremy Webb, Nicholas B. Larson, et al.. (2022). Added value of mass characteristic frequency to 2-D shear wave elastography for differentiation of benign and malignant thyroid nodules. Ultrasound in Medicine & Biology. 48(8). 1663–1671. 1 indexed citations

11.

Kotwal, Anupam, Michael P. Gustafson, Svetlana Bornschlegl, et al.. (2020). Immune Checkpoint Inhibitor-Induced Thyroiditis Is Associated with Increased Intrathyroidal T Lymphocyte Subpopulations. Thyroid. 30(10). 1440–1450. 54 indexed citations

12.

Furmaniak, Jadwiga, Jane Sanders, Paul W. Sanders, et al.. (2020). Practical applications of studies on the TSH receptor and TSH receptor autoantibodies. Endocrine. 68(2). 261–264. 9 indexed citations

13.

Kotwal, Anupam, Lisa A. Kottschade, & Mabel Ryder. (2019). PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients. Thyroid. 30(2). 177–184. 123 indexed citations

14.

Chintakuntlawar, Ashish V., Jun Yin, Robert L. Foote, et al.. (2019). A Phase 2 Study of Pembrolizumab Combined with Chemoradiotherapy as Initial Treatment for Anaplastic Thyroid Cancer. Thyroid. 29(11). 1615–1622. 57 indexed citations

15.

Iñiguez‐Ariza, Nicole M., Mabel Ryder, Crystal Hilger, & Keith C. Bible. (2017). Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer. Thyroid. 27(7). 923–927. 28 indexed citations

16.

Iñiguez‐Ariza, Nicole M., Keith C. Bible, John C. Morris, et al.. (2017). NTRK1-3 point mutations in poor prognosis thyroid cancers.. Journal of Clinical Oncology. 35(15_suppl). 6087–6087. 1 indexed citations

17.

Ryder, Mabel, Margaret K. Callahan, Michael A. Postow, Jedd D. Wolchok, & James A. Fagin. (2014). Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocrine Related Cancer. 21(2). 371–381. 344 indexed citations

18.

Ryder, Mabel, Matti L. Gild, Tobias M. Hohl, et al.. (2013). Genetic and Pharmacological Targeting of CSF-1/CSF-1R Inhibits Tumor-Associated Macrophages and Impairs BRAF-Induced Thyroid Cancer Progression. PLoS ONE. 8(1). e54302–e54302. 116 indexed citations

19.

Montero‐Conde, Cristina, Sergio Ruiz‐Llorente, José Miguel Domínguez, et al.. (2013). Abstract 3402: Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF mutant thyroid carcinomas.. Cancer Research. 73(8_Supplement). 3402–3402. 2 indexed citations

20.

Ricarte‐Filho, Julio C., Mabel Ryder, Dhananjay Chitale, et al.. (2009). Mutational Profile of Advanced Primary and Metastatic Radioactive Iodine-Refractory Thyroid Cancers Reveals Distinct Pathogenetic Roles for BRAF, PIK3CA , and AKT1. Cancer Research. 69(11). 4885–4893. 420 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact